
pmid: 31185206
Combined inhibitions of PARP and DNA damage checkpoint have the potential for high anti-cancer efficacy, but concurrent inhibitions have been hampered by intolerable side effects. In this issue of Cancer Cell, Fang and colleagues (Fang et al., 2019) propose that sequential inhibitions of PARP and DNA damage checkpoint considerably widen the therapeutic window.
Neoplasms, Humans, Nuclear Proteins, Cell Cycle Proteins, Cell Cycle Checkpoints, Poly(ADP-ribose) Polymerase Inhibitors, Protein-Tyrosine Kinases
Neoplasms, Humans, Nuclear Proteins, Cell Cycle Proteins, Cell Cycle Checkpoints, Poly(ADP-ribose) Polymerase Inhibitors, Protein-Tyrosine Kinases
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 4 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
